On March 6, 2024, Rakuten Medical, Inc. closed the transaction. The company has raised $45,000,000 in this transaction. As on the same date, the company has received $13,872,798.18 in its second and final tranche from new investors, Hikma Pharmaceuticals PLC, Dai-ichi Life Holdings, Inc., Mizuho Bank, Ltd., returning investors, Rakuten Ventures, SBI Holdings, Inc., Investment Arm and individual investor, Mickey Mikitani.

The company has issued non-convertible series E preferred stock in the transaction. As part of the transaction, Mazen Darwazah from Hikma Pharmaceuticals PLC will join the company's board of directors.